Alzheimer's disease: Low levels of peptide a-amidation activity in brain and CSF

Gary S Wand, C. May, V. May, P. J. Whitehouse, S. I. Rapoport, B. A. Eipper

Research output: Contribution to journalArticle

Abstract

Carboxyl terminal a-amidation confers biologic activity to many neuropeptides. Levels of a-amidating activity, peptidyl-glycine α-amidating monooxygenase (PAM), were reduced in the CSF of patients with dementia of the Alzheimer type (DAT) compared with healthy, age-matched controls. Repeat lumbar puncture data revealed a decline in CSF PAM activity of approximately 16% per year in DAT patients. Of the cerebral cortical regions examined, only the temporal pole showed reduced PAM activity in patients with Alzheimer's disease (AD) compared with controls. These studies may indicate selective dysfunction of neurons which normally synthesize biologically active, a-amidated peptides in the CNS of AD patients.

Original languageEnglish (US)
Pages (from-to)1057-1061
Number of pages5
JournalNeurology
Volume37
Issue number6
StatePublished - 1987

Fingerprint

Alzheimer Disease
Mixed Function Oxygenases
Glycine
Peptides
Brain
Spinal Puncture
Central Nervous System Diseases
Neuropeptides
Neurons
Alzheimer's Disease
Dementia
Alzheimer

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Wand, G. S., May, C., May, V., Whitehouse, P. J., Rapoport, S. I., & Eipper, B. A. (1987). Alzheimer's disease: Low levels of peptide a-amidation activity in brain and CSF. Neurology, 37(6), 1057-1061.

Alzheimer's disease : Low levels of peptide a-amidation activity in brain and CSF. / Wand, Gary S; May, C.; May, V.; Whitehouse, P. J.; Rapoport, S. I.; Eipper, B. A.

In: Neurology, Vol. 37, No. 6, 1987, p. 1057-1061.

Research output: Contribution to journalArticle

Wand, GS, May, C, May, V, Whitehouse, PJ, Rapoport, SI & Eipper, BA 1987, 'Alzheimer's disease: Low levels of peptide a-amidation activity in brain and CSF', Neurology, vol. 37, no. 6, pp. 1057-1061.
Wand GS, May C, May V, Whitehouse PJ, Rapoport SI, Eipper BA. Alzheimer's disease: Low levels of peptide a-amidation activity in brain and CSF. Neurology. 1987;37(6):1057-1061.
Wand, Gary S ; May, C. ; May, V. ; Whitehouse, P. J. ; Rapoport, S. I. ; Eipper, B. A. / Alzheimer's disease : Low levels of peptide a-amidation activity in brain and CSF. In: Neurology. 1987 ; Vol. 37, No. 6. pp. 1057-1061.
@article{300ea9cec81f467f890cb9b1e6985978,
title = "Alzheimer's disease: Low levels of peptide a-amidation activity in brain and CSF",
abstract = "Carboxyl terminal a-amidation confers biologic activity to many neuropeptides. Levels of a-amidating activity, peptidyl-glycine α-amidating monooxygenase (PAM), were reduced in the CSF of patients with dementia of the Alzheimer type (DAT) compared with healthy, age-matched controls. Repeat lumbar puncture data revealed a decline in CSF PAM activity of approximately 16{\%} per year in DAT patients. Of the cerebral cortical regions examined, only the temporal pole showed reduced PAM activity in patients with Alzheimer's disease (AD) compared with controls. These studies may indicate selective dysfunction of neurons which normally synthesize biologically active, a-amidated peptides in the CNS of AD patients.",
author = "Wand, {Gary S} and C. May and V. May and Whitehouse, {P. J.} and Rapoport, {S. I.} and Eipper, {B. A.}",
year = "1987",
language = "English (US)",
volume = "37",
pages = "1057--1061",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Alzheimer's disease

T2 - Low levels of peptide a-amidation activity in brain and CSF

AU - Wand, Gary S

AU - May, C.

AU - May, V.

AU - Whitehouse, P. J.

AU - Rapoport, S. I.

AU - Eipper, B. A.

PY - 1987

Y1 - 1987

N2 - Carboxyl terminal a-amidation confers biologic activity to many neuropeptides. Levels of a-amidating activity, peptidyl-glycine α-amidating monooxygenase (PAM), were reduced in the CSF of patients with dementia of the Alzheimer type (DAT) compared with healthy, age-matched controls. Repeat lumbar puncture data revealed a decline in CSF PAM activity of approximately 16% per year in DAT patients. Of the cerebral cortical regions examined, only the temporal pole showed reduced PAM activity in patients with Alzheimer's disease (AD) compared with controls. These studies may indicate selective dysfunction of neurons which normally synthesize biologically active, a-amidated peptides in the CNS of AD patients.

AB - Carboxyl terminal a-amidation confers biologic activity to many neuropeptides. Levels of a-amidating activity, peptidyl-glycine α-amidating monooxygenase (PAM), were reduced in the CSF of patients with dementia of the Alzheimer type (DAT) compared with healthy, age-matched controls. Repeat lumbar puncture data revealed a decline in CSF PAM activity of approximately 16% per year in DAT patients. Of the cerebral cortical regions examined, only the temporal pole showed reduced PAM activity in patients with Alzheimer's disease (AD) compared with controls. These studies may indicate selective dysfunction of neurons which normally synthesize biologically active, a-amidated peptides in the CNS of AD patients.

UR - http://www.scopus.com/inward/record.url?scp=0023255792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023255792&partnerID=8YFLogxK

M3 - Article

C2 - 3587629

AN - SCOPUS:0023255792

VL - 37

SP - 1057

EP - 1061

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -